ADPS topical - Taro Pharmaceuticals USA

Drug Profile

ADPS topical - Taro Pharmaceuticals USA

Latest Information Update: 19 May 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Taro Pharmaceuticals USA
  • Class Antiacnes; Antibacterials
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Acne vulgaris

Most Recent Events

  • 01 Apr 2017 Taro Pharmaceuticals completes a phase II trial in Acne vulgaris (In children, In adolescents, In adults) in USA (NCT02935036)
  • 01 Oct 2016 Phase-II clinical trials in Acne vulgaris (In children, In adolescents, In adults) in USA (Topical) (NCT02935036)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top